Fly News Breaks for November 1, 2019
Nov 1, 2019 | 09:29 EDT
Needham analyst Chad Messer raised his price target on Cytokinetics to $24 and kept his Buy rating, saying he is including CK-274 in his valuation after its phase 1 results presented last month. The analyst notes that he continues to view omecamtiv as the "backbone" in valuation model given the "enormous unmet need in heart failure."
News For CYTK From the Last 2 Days
There are no results for your query CYTK